Document resource
Herpes simplex virus (HSV) in pregnancy is important for all those treating neonates across neonatal, maternity and paediatric settings. There is a risk of neonatal transmission in the genital tract or postnatally, and HSV has the potential for serious sequelae in neonates. HSV mortality is estimated at 29% for disseminated disease, 4% for central nervous system (CNS) disease and 0% for isolated skin, eye and mouth (SEM) disease. Among survivors, 17% of those with disseminated disease, 31% of those with CNS disease and 2% of those with SEM are estimated to have neurodevelopmental complications.1